SCHEDULE 13G: State Street Corporation Discloses 4.9% Passive Stake in Halozyme Therapeutics

State Street Corporation has reported a passive 4.9% beneficial ownership stake in Halozyme Therapeutics Inc., holding 6,053,007 shares of common stock as of March 31, 2025.

Summary

• State Street Corporation, a Massachusetts-based financial services company, has filed a Schedule 13G indicating its beneficial ownership in Halozyme Therapeutics Inc.
• As of March 31, 2025, State Street Corporation beneficially owns 6,053,007 shares of Halozyme Therapeutics Inc. common stock.
• This ownership represents 4.9% of the class of securities.
• State Street Corporation holds shared voting power over 5,562,493 shares and shared dispositive power over all 6,053,007 shares.
• The filing is made under Rule 13d-1(b), signifying a passive investment, not intended to change or influence control of the issuer.
• The shares are held in the ordinary course of business by State Street and its investment adviser subsidiaries, including SSGA Funds Management, Inc. and State Street Global Advisors entities.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G) by an institutional investor, indicating a passive stake. It contains no positive or negative operational or financial news about the issuer, Halozyme Therapeutics Inc., and is purely informational regarding ownership.

Positives

• Indicates a significant institutional investor, State Street Corporation, holds a substantial stake in Halozyme Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The passive nature of the filing (Rule 13d-1(b)) suggests the investment is for portfolio management rather than activist intent, which can be viewed as a stable holding.

Negatives

• No specific negative information is disclosed in this Schedule 13G filing, as it primarily reports beneficial ownership.

Risks

• This filing does not detail specific risks related to Halozyme Therapeutics Inc. beyond the inherent market risks associated with holding common stock.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Halozyme Therapeutics Inc.'s future outlook, as its purpose is solely to disclose beneficial ownership.

Management Comments

• Elizabeth Schaefer, Senior Vice President, Chief Accounting Officer of State Street Corporation, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

This filing reflects a routine disclosure by a major institutional asset manager, State Street Corporation, regarding its passive investment in a biotechnology company, Halozyme Therapeutics Inc. Such filings are common for large investment firms managing diverse portfolios and do not typically indicate a strategic shift or activist intent, but rather a standard portfolio holding within the healthcare or biotech sector.

Comparison to Industry Standards

• This document is a beneficial ownership disclosure and does not contain financial results or operational data that would allow for a direct comparison to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, potentially offering a degree of stability by indicating a long-term, non-activist investment.
• Management: Confirms that a large institutional investor holds shares without intent to influence control, allowing management to focus on existing strategic plans.

Next Steps

• State Street Corporation will be required to file an amendment to this Schedule 13G if its beneficial ownership percentage changes by more than 1% or if its investment intent changes from passive to active.

Key Dates

Keywords

Halozyme Therapeutics, State Street Corporation, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, financial services, biotechnology